Caricamento quotazioni...
Previsioni
| Acquista |
1 |
| Mantieni |
0 |
| Vendi |
0 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
Valneva stock rises 23% after EMA begins approval review for tick vaccine
Valneva shares jumped nearly 23% and climbed back above the 200-day moving average, cutting the year-to-date loss to 19%. The move follows positive Phase III data for the tick vaccine PF-07307405, developed with Pfizer; the European Medicines Agency is now reviewing it for approval. Jefferies analyst Maury Raycroft also sees FDA approval of the U.S. filing as likely and assigns a $15 price target to the U.S. warrants. » Altro su de.investing.com
Valneva cuts guidance after disappointing half-year loss
Valneva reports a net loss of €63.3m for H1 2026, worsened gross margins, declining travel vaccine sales and one‑off charges, which caused revenue and operating profit to decline. The company lowered its 2026 product sales forecast to €135–150m and total revenue to €145–160m, citing weakening demand in key markets. The share price came under pressure after the report, while progress on the restructuring and the Lyme disease programme with Pfizer are seen as longer‑term catalysts. » Altro su de.investing.com
Valneva beats expectations in Q4 2025, stock rises
Valneva reported Q4 2025 EPS of -$0.24 (forecast -$0.3693) and revenue of $55.17m (expectation $50.56m); the stock rose 2.82% in pre-market trading to $11.32. The full-year results show total revenue of over €170m and a 9% increase in sales of its own products, while operating loss (€82.1m) and net loss (€115.2m) were weighed down by higher R&D spending. Valneva emphasizes focus on its vaccine portfolio, notably Lyme disease and chikungunya, expects Phase-3 data for Lyme disease in H1 2026 and forecasts revenue of around $204.39m for 2026. Risks remain regulatory approvals, market acceptance and geopolitical/structural challenges. » Altro su de.investing.com
Valneva cuts 2026 sales forecast after scaling back third-party distribution
Valneva reported total revenue of €174.7m for 2025 (2024: €169.6m) and growth in its own-product sales, while overall product revenues fell 3.3% to €157.9m. The decline was driven mainly by a 42% collapse in third-party distribution to €19.2m. For 2026 the company is guiding total revenue of €155–170m and product revenues of €145–160m, below consensus estimates; Valneva cites the ongoing wind-down of third-party product distribution as the reason. Cash and cash equivalents fell to €109.7m at year-end; hopes remain pinned on the Phase III VALOR study against Lyme disease and Phase II data for the Shigella candidate in H2 2026. » Altro su de.investing.com
Valneva withdraws US application for chikungunya vaccine
Valneva voluntarily withdrew its BLA and IND applications for its chikungunya vaccine IXCHIQ in the US after the FDA imposed a clinical hold. The move follows an investigation of a recently reported serious adverse event abroad in an adult who received three vaccines simultaneously; a causal link to IXCHIQ is plausible but not definitively established. The stock fell about 6.6% in premarket trading. Valneva said it will gather further information and, after additional discussions with regulators, continue planned post‑marketing clinical activities; the benefit‑risk profile for already approved regions remains favorable. » Altro su de.investing.com
Dati finanziari dell'azienda
| (EUR) | giugno 2026 | YoY |
|---|---|---|
| Ricavi | 34,94 Mln | 27,71% |
| Utile lordo | 1,6 Mln | 93,40% |
| Utile netto | -31,2 Mln | 169,32% |
| EBITDA | -22,53 Mln | 2745,20% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 489,39 Mln € |
Numero di azioni | 190,25 Mln |
Massimo/minimo a 52 settimane | 5,15 € - 2,03 € |
| Dividendi | No |
Beta | 1,41 |
Rapporto P/E | -2,85 |
Rapporto PEG | 0,04 |
Rapporto P/B | 6,00 |
Rapporto P/S | 3,42 |
Profilo aziendale
Valneva SE, un'azienda specializzata in vaccini, si concentra sullo sviluppo e sulla commercializzazione di vaccini profilattici per malattie infettive con bisogni medici insoddisfatti. I suoi vaccini commerciali per viaggiatori includono IXIARO, un vaccino inattivato contro l'encefalite giapponese, prodotto su colture cellulari Vero, indicato per l'immunizzazione attiva contro l'encefalite giapponese; DUKORAL, un vaccino orale per la prevenzione della diarrea causata dal batterio Vibrio cholerae e/o da Escherichia coli enterotossigeno che produce la tossina termolabile; e VLA2001, un candidato vaccino contro SARS-CoV-2. L'azienda sviluppa inoltre VLA15, un candidato vaccino che ha completato la sperimentazione clinica di Fase II contro Borrelia, e VLA1553, un candidato vaccino in sperimentazione clinica di Fase III contro il virus chikungunya. Vende i propri prodotti negli Stati Uniti, in Canada, Germania, Austria, paesi nordici, Regno Unito, altri paesi europei e a livello internazionale. Valneva SE ha collaborazioni con Pfizer, Inc. per co-sviluppare e commercializzare il suo vaccino contro la malattia di Lyme; e con l'Instituto Butantan per lo sviluppo, la produzione e la commercializzazione di un vaccino monodose contro il chikungunya. L'azienda è stata fondata nel 1998 ed ha sede a Saint-Herblain, in Francia.
| Nome | Valneva |
| CEO | Thomas Lingelbach |
| Sede centrale | Saint-Herblain,
ge Francia |
| Sito web | |
| Settore | Sanità |
| Industria | Biotecnologia |
| Quotazione in borsa | 29/06/2007 |
| Dipendenti | 674 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
Euronext | VLA.PA |
London Stock Exchange | 0OB3.L |
Pnk | INRLF |
XETRA | AYJ.DE |
Frankfurt | AYJ.F |
Düsseldorf | AYJ.DU |
Hamburg | AYJ.HM |
London | 0OB3.L |
Paris | VLA.PA |
München | AYJ.MU |
Wien | VLA.VI |
SIX | VLA.SW |